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Developing a blockchain-based supply chain 
system for advanced therapies: study protocol 
 
Abstract 
 
Background: Advanced therapies, including cell and gene therapies, have shown therapeutic 
promise in curing life-threatening diseases such as leukaemia and lymphoma. However, they 
can be complicated and expensive to deliver due to their sensitivity to environment, 
troublesome tissue, cell, or genetic material sourcing and complicated regulatory 
requirements. 
 
Aim and objectives: 
This study aims to create a novel connected supply chain logistics and manufacturing 
management platform based on blockchain, with cell and gene therapy as a use case. 
Objectives are to define the requirements and perform feasibility evaluations on the use of 
blockchain for standardized manufacturing and establishment of chain of custody for the 
needle-to-needle delivery of autologous cell and gene therapies. A way of lowering overall 
regulatory compliance costs for running a network of facilities operating similar or parallel 
processes will be evaluated by lower monitoring costs through publishing zero-knowledge 
proofs and product release by exception. 
 
Methods: 
The study will use blockchain technologies to digitally connect and integrate supply chain 
with manufacturing to address the security, scheduling and communication issues between 
advanced therapy treatment centres and manufacturing facilities in order to realise a 
transparent, secure, automated and cost-effective solution to the delivery of these life-
saving therapies. An agile software development methodology will be used to develop, 
implement, and evaluate the system. The system will adhere to EU and US Good 
Manufacturing Practices and regulatory requirements. 
 
Discussion: 
The successful implementation of the integrated blockchain solution to supply chain and 
manufacturing of advanced therapies can push the industry standards towards a safer and 
more secure therapy delivery process.  
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Introduction 
 
Advanced Therapy Medicinal Products (ATMPs) industries, including cell therapy and gene 
therapy, are forecasted to grow at a compound annual growth rate (CAGR) of 22% between 
2018-2022 [1]. ATMPs are estimated to be a billion Eurodollar industry and potentially the 
fourth therapeutic pillar of healthcare [2,3]. Commercially available ATMPs make up a very 
small percentage of total patient interventions as compared to mainstream 1st and 2nd line 
therapies in the developed markets. However, for cell and gene therapy they are expected 
to grow from a few 1000 patients in 2018/19 globally to possibly 100m by 2025 as the 
number of ATMPs commercially available matures [1].   
 
To facilitate the growth of the ATMP sector, the supply chain infrastructure is critical in 
supporting the industry from clinical trials to commercial distribution to provide life-saving 
treatments to more patients in a safer and more secure manner. In addition, compliance 
with data protection laws (Health Insurance Portability and Accountability Act [HIPAA] in the 
US and General Data Protection Regulation [GDPR] in EU) come with a very high cost [4–6]. 
Without proper encryption and selective data disclosure, everyone in the supply chain will 
have to be GDPR compliant. Key to the success of these new treatments will be the safe, 
secure and timely delivery of advanced therapies in a highly regulated environment (e.g. 
temperature, tilt, time duration, location) to ensure transparency and accuracy [7,8]. 
 
Current logistics tracking solutions are reliant on paper audit trails and legacy cloud 
infrastructure and are at significant risk to causing treatment failure. Specific to autologous 
therapies, the starting material collected from the patients can vary greatly. This can cause 
the final manufactured product to be of different quality and may fall out of specification[9]. 
For example, Novartis had to write off multiple batches of Kymriah (Novartis, Basel, 
Switzerland) due to out-of-specification products since its launch in August 2017 in the 
US[10]. Also, during the clinical studies, 7-9% of patients did not receive the CAR-T 
treatment due to manufacturing failures [11].  
 
Current solutions, using paper and dated legacy standalone IT infrastructure that are being 
used by bioscience companies’ pre-commercialisation maybe sufficient during research, but 
is likely to fail as their operations scale up and out. They are not designed to be scalable, 
interoperable or able to deal with the complexity of regulation and process that these 
ATMPs will incur as you enter the real world of patient care. Batch identification through 
patient initials and date of birth is considered insufficient due to possible mix-ups which can 
be catastrophic for patients. Intuitive labelling methods must be simple enough for use 
across sites whilst providing sufficient information about the patient to avoid mix-ups [12]. 
Companies, including Trakcel, Vineti, Danaher (previously GE), are using cloud-based 
solutions for manufacturing ATMPs [13–15]. Whilst cloud-based solutions systems are useful 
in tracking and tracing products in traditional linear logistic supply chains, data in these 
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centralised systems are highly vulnerable to being tampered with, potentially allowing 
fraudulent or damaged products entering the supply chain or data falsification. These 
systems focus only on the logistics part of the delivery process and fail to address the 
coordination issue between stakeholders (hospitals, patients, manufacturers, logistics 
providers, regulatory authorities) in advanced therapy delivery process.  
 
As new licence indications are achieved, the systems will need to be designed to change and 
adapt across the whole logistics supply chain. From the collection of source material to the 
manufacturing and final delivery of therapies, there are many hand-off points and hence the 
probability of mix-ups and supply chain failure. As most advanced therapies are given as the 
last line of treatment for critically ill patients, the failure or delay may cost them their 
chance of survival.  
 
Blockchain technology is a digital ledger of transactions, agreements and controls that are 
stored in a distributed network, removing the need for a centralised database. Due to its 
distributed and transparent nature, data stored cannot be tampered with and is 
transparent, traceable and secure [16,17]. The benefits of the technology have been 
explored in various sectors including finance, healthcare and agriculture[18–20] and one of 
the most highly discussed use case is in supply chain management. Integration of blockchain 
into supply chain architecture can lead to a more reliable, transparent and resilient 
system[21–24]. Specific to ATMP supply chain management, a layered blockchain solution 
with a smart contracts business logic layer can enable a holistic way of managing various 
stakeholders, ensure needle-to-needle supply chain integrity and secure data management. 
The decentralised nature of blockchain can allow this to happen almost instantaneously 
across the full ecosystem, including the ability to keep regulators updated by publishing on a 
public chain with zero-knowledge proofs. This is something that cloud environments cannot 
do and requires on-site regulation by regulators. The protocol of this study will focus on 
developing a patient-to-patient blockchain-based supply chain system for advanced 
therapies.  
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Methods  
Description of the blockchain-based supply chain system  
This study aims to create a smart and connected supply chain logistics and manufacturing 
management platform based on blockchain, with cell and gene therapy as a use case. The 
data collected from sensors can be better connected using an interactive platform to 
improve coordination between stakeholders. To ensure the security of this platform which 
contains sensitive information from patient data to manufacturing protocols, blockchain 
allows a transparent, incorruptible yet encrypted way of tracking and tracing the 
environmental conditions of advanced therapies from its origins to final administration. This 
is particularly important to advanced therapies due to the requirement of cold chain 
delivery and the sensitivity of live cell products to fluctuations in the environment. The 
platform technology will allow real-time and centralised monitoring of the needle-to-needle 
process without compromising patient data security through selective disclosure of 
information. 
Publishing zero-knowledge proofs when all steps are completed according to 
standard protocol can allow regulatory authorities and manufacturers with multiple 
collection centres and manufacturing facilities to manage by exception instead of looking 
through all data points and paper batch records to find regulatory breaches, allowing a 
reduction in regulatory monitoring costs. This can help improve consistency in all steps of 
collection, manufacturing and delivery across centres and allow issues to be identified and 
the process to be improved through learning from data. The system will adhere to EU and 
US Good Manufacturing Practices and industry bodies for healthcare distribution 
requirements. 
 
Development and evaluation 
This study will involve the components outlined in Table 1. An agile framework will be used 
for the development and evaluation of the system [25].  
 
Table 1 Components of agile development and evaluation 
Nr Components 
1 Stakeholder analysis 
2 Customise and implement track and trace software platform  
3 Migration and integration of software to blockchain platform  
4 Case study for evaluation of the system 
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1. Stakeholder analysis 
A detailed stakeholder map shall be derived, including the manufacturer of therapies, 
healthcare professionals who engage with the therapy delivery pathway, payors of the 
treatment for visibility of the chain of custody of the ATMP, the advanced therapy 
treatment centre (ATTC), hospital IT system implementation partner, supply chain track-
and-trace provider, logistics provider, manufacturing facilities (including contract 
manufacturers), and regulatory authorities. Focus group meetings will be held to 
understand the points where regulatory/monitoring costs arises; how a network of facilities 
are currently managed; the data that needs to be collected at different points of the supply 
chain to enable cheaper monitoring and product release by exception. Outcomes will be 
user requirement specification for decentralised manufacturing, standardized workflow for 
target therapy, understand the capability and gaps in and across current systems.  
 
2. Customise track and trace software platform  
The design of minimum viable eco-system and definition of scope of work for each party will 
be produced. A working prototype track and trace software platform for autologous 
advanced therapies has been developed and will be customised to cell and gene therapy. 
For regulatory activities, we will extend existing regulatory approval to complete preliminary 
pathways for support of our new product. The platform will be designed so that it can be 
easily integrated into existing commercial applications or be a standalone solution if 
required. A customised prototype will be developed to demonstrate the platform. 
 
3. Migration and integration of software to blockchain platform  
The prototype track and trace software platform will be adapted to combine characteristics 
of linear and circular supply chain for advanced therapies. Key outcomes to monitor will be 
communication time reduction; capacity utilization; resource sharing and utilization; ease of 
establishing process comparability across manufacturing facilities; delivery accuracy and 
number of mix-ups/failures; user satisfaction (ease of use, interoperability, etc). 
The core code of blockchain technology platform for solutions currently developed 
are patented in the US and EU [26]. Compared to existing local electronic batch record 
system and cloud-based solutions, a blockchain-based platform will allow for a more secure 
way of recording and storing supply chain data on a distributed ledger and encrypted to 
make blockchain technology tamper proof. Any divergence or discrepancy to the ledger of 
information captured will be flagged to all, including the authorities.  
Participating parties can manage the system so that only the relevant information is 
made available to each party. A blockchain solution facilitates partnerships between parties 
with divergent commercial self-interests leveraging automated smart contracts. Each party 
is kept honest as the collective objectives of all consortium members using the blockchain 
solution will not be beneficial to any of the members if members were to collude. Real-time 
and up-to-date manufacturing process updates to be transparent for patients and hospital 
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staff in order to allow more efficient scheduling and resource allocation for treatment 
preparation. This means that the hospital can provide patient status updates to 
manufacturing. Information on the blockchain can be encrypted and selectively available to 
approved parties, hence reducing the number of European General Data Protection 
Regulation (GDPR) trained staff, thus lowering the cost of compliance.  
Through integrating the track-and-trace and manufacturing execution system, 
greater coordination between stakeholders can be fostered, allowing the delivery process to 
be more efficient and releasing valuable time of skilled workers for value-added work. Good 
track and trace documentation will allow manufacturers and hospitals to go back and look 
at what may have happened differently to better understand what can improve the 
outcomes and hence improve the quality and consistency of raw material collection and 
manufacturing process.  
Use of blockchain will ensure data integrity between the various systems, scanners 
and data input devices without having to make substantial integration changes. Also, this 
creates efficiencies through automating payment processes, regulatory reporting, 
compliance and audit. Also, this technology can lower the cost of regulatory compliance 
through publishing zero-knowledge proofs where all standard protocols are done properly, 
removing the need for going through all records (on paper or in cloud) and the cost of GDPR 
compliance training through encryption of patient data and implementation of multiple 
levels of access rights.  
 
4. Case study 
This investigation will be structured via a six-stage process for case study investigations 
[27]to evaluate the system’s feasibility and economic impact. A case study will provide a 
structured means to generate evidence to subsequently evaluate such claims by collecting 
baseline data for further evaluation. Understanding the feasibility and economic impacts of 
blockchain for cell therapy in a decentralized fashion at different levels of automation, 
different demand levels and scale of system. Project outcomes appraisal and simulate the 
impacts of widespread use of this methodology for larger systems through modelling. The 
results will be disseminated through publications and conference presentations. 
 
Table 1. Case study framework 
Stage  Outcome 
Plan Case description and linking of case approach to investigation outcomes. 
Design  Construction of research design and linkage of research questions, data, and 
criteria for evaluation and synthesis. 
Prepare  Draft, execution, and approval of study protocols. 
Collect Data collection strategy. 
Analyze Data extracted into categories for review and analyzed.  
Share The findings will be presented in a report for publication in a peer-reviewed 
journal. 
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Discussion 
The successful implementation of the integrated blockchain solution to supply chain and 
manufacturing of advanced therapies can push the industry standards towards a safer and 
more secure therapy delivery process and encourage rapid adoption of the innovative 
technology. Adoption of the innovation in a wider context can reduce the cost of monitoring 
good manufacturing practices through increased transparency and security of the 
manufacturing and delivery process. A more transparent process can reduce communication 
errors and overall time spent, hence reducing healthcare costs. The integrated platform 
solution will enable more accurate and transparent tracking at all stages of the needle-to-
needle delivery pipeline, allowing treatment centric care pathways to be truly personalized 
through a digital evolution in supply chain and manufacturing management.  
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